Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 12:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 125 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tenofovir Disoproxil Fumarate 300 mg daily Clear all
Completed Phase 1 Interventional

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

NCT00545558
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Cincinnati, Ohio • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen

NCT01940471
View directory record Official record
Conditions
HBeAg-positive Chronic Hepatitis B
Interventions
TAF, TDF, TAF Placebo, TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 2 Interventional Results available

Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States

NCT00936715
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
FTC/TDF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 3 Interventional Results available

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, COBI, ATV, DRV, NRTI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Switching From Epzicom to Truvada

NCT00724711
View directory record Official record
Conditions
HIV Infection
Interventions
emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), abacavir (ABC)/lamivudine (3TC)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
73
States / cities
Little Rock, Arkansas • Beverly Hills, California • Fountain Valley, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Assessment of a New "Boosting" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers

NCT03202511
View directory record Official record
Conditions
Pre-Exposure Prophylaxis
Interventions
Probenecid Oral Tablet, Tenofovir disoproxil fumarate/Emtricitabine
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 11, 2026, 12:12 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma

NCT01528865
View directory record Official record
Conditions
Lymphoma
Interventions
Lamivudine, Tenofovir disoproxil fumarate
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status

NCT01040091
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine (FTC), Tenofovir disoproxil fumarate (TDF), Efavirenz (EFV), Truvada
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 3 Interventional Results available

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

NCT01003990
View directory record Official record
Conditions
HIV
Interventions
Atazanavir, Atazanavir/Ritonavir, Tenofovir/Emtricitabine, Lopinavir/ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 4 Interventional Results available

Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis

NCT00108862
View directory record Official record
Conditions
HIV Infection, Tuberculosis
Interventions
Strategy: Immediate ART, Strategy: Deferred ART
Other
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
13 Years and older
Enrollment
809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 2 Interventional Results available

Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection

NCT00959894
View directory record Official record
Conditions
HIV Infections
Interventions
Etravirine (Intelence), Truvada
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

NCT01252940
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/RPV/TDF, PI, RTV, NRTIs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
66
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 2 Interventional Results available

Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART

NCT01903031
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Nuvaring, EFV, ATV/r, TDF, NRTIs
Device · Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 11, 2026, 12:12 AM EDT
Terminated Phase 3 Interventional Results available

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

NCT01345630
View directory record Official record
Conditions
HIV-1
Interventions
Maraviroc, Emtricitabine/tenofovir, darunavir/ritonavir 800/100 mg, placebo for emtricitabine/tenofovir, placebo for maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
84
States / cities
Birmingham, Alabama • Hobson City, Alabama • Hayward, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

NCT00892437
View directory record Official record
Conditions
HIV-1 Infection
Interventions
COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection

NCT03576066
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H0731, SOC NUC, Placebo Oral Tablet
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
17
States / cities
Beverly Hills, California • Coronado, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men

NCT01140880
View directory record Official record
Conditions
HIV Seroconversion, Stimulant Abuse
Interventions
Truvada
Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 4 Interventional Results available

Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

NCT01448616
View directory record Official record
Conditions
Herpes Simplex Type II
Interventions
TDF, Placebo Vaginal Gel, Vaginal TFV Gel, Placebo Tablets
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

NCT00869557
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Stribild, Atripla
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
30
States / cities
Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 2 Interventional Results available

Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men

NCT00856323
View directory record Official record
Conditions
Amphetamine-Related Disorders, HIV, HIV Infections
Interventions
Truvada, CM
Drug · Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection

NCT00414518
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate/Emtricitabine, Lopinavir/Ritonavir
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Denver, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 11, 2026, 12:12 AM EDT
Withdrawn Phase 2 Interventional

Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation

NCT01515813
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Pravastatin sodium, Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
9
States / cities
Los Angeles, California • Torrance, California • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

NCT01780506
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
78
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 11, 2026, 12:12 AM EDT
Completed Phase 1Phase 2 Interventional

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children

NCT00260078
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Darunavir, Efavirenz, Nevirapine, Ritonavir, Tenofovir disoproxil fumarate, Pharmacokinetic Study
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
21
States / cities
Alhambra, California • La Jolla, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 11, 2026, 12:12 AM EDT